Citigroup
AVNR

Citigroup’s AVANIR PHARMACEUTICALS, INC CL A AVNR Stock Holding History

Citigroup’s Portfolio AVNR Stock Details AVNR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q1 		– Sell
-293,656
Closed -$4.98M – 7785
2014
Q4 		$4.98M Buy
293,656
+287,657
+4,795% +$4.05M ﹤0.01% 1799
2014
Q3 		$72K Buy
5,999
+2,380
+66% +$16.3K ﹤0.01% 5038
2014
Q2 		$20K Sell
3,619
-32,919
-90% -$152K ﹤0.01% 5818
2014
Q1 		$134K Sell
36,538
-27,553
-43% -$105K ﹤0.01% 4722
2013
Q4 		$215K Buy
64,091
+22,782
+55% +$94.1K ﹤0.01% 4596
2013
Q3 		$175K Buy
41,309
+34,597
+515% +$164K ﹤0.01% 4270
2013
Q2 		$31K Buy
+6,712
New +$23.1K ﹤0.01% 5628

Citigroup's AVNR Position: Q1 2015 in Review

Citigroup sold out of AVANIR PHARMACEUTICALS, INC CL A (AVNR) in Q1 2015, closing a stake of 293,656 shares — an estimated $4.98M sold.

Citigroup first reported a position in AVNR in Q2 2013 and held it in 7 quarters. The position peaked at $4.98M in Q4 2014. 0 funds tracked by Wall St. Rank hold AVNR as of Q1 2015.

  • Citigroup reported no remaining AVANIR PHARMACEUTICALS, INC CL A position as of Q1 2015 after selling out during the quarter.
  • Citigroup sold 293,656 AVANIR PHARMACEUTICALS, INC CL A shares in Q1 2015, an estimated $4.98M.
  • Citigroup first reported a position in AVANIR PHARMACEUTICALS, INC CL A in Q2 2013 and held it in 7 quarters.
  • Citigroup's AVANIR PHARMACEUTICALS, INC CL A position peaked at $4.98M in Q4 2014.
  • 0 funds tracked by Wall St. Rank held AVANIR PHARMACEUTICALS, INC CL A as of Q1 2015.

Based on Citigroup's 13F filing for Q1 2015, filed 14 May 2015.